Based on the SPR results, we expected that MB2033 would demonstrate greater functional affinity for hPD-L1 expressed on tumor cells relative to its affinity for IL-2Rs on immune cells when compared with WT IL-2-based immune cytokines (Fig. 2b). Here, IL2 is linked to neoplasm.